26 November 2020Muireann Bolger

Five minutes with… Jacqueline Mulryne

Amid the unprecedented challenges presented by COVID-19, questions around the use of second medical use (SMU) patents have become increasingly pertinent. On Tuesday December 1, LSPN Connect ’s session: Addressing Second Medical Use Infringement: An Evaluation of Recent SMU Cases will examine a number of key issues relating to this pivotal area of life sciences IP.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Five minutes with… Dmitry Karshtedt

5 July 2021 Genus claims—or patent claims covering a family of related compounds—are commonplace in life sciences patent law. But following a rising trend of invalidity rulings, the future of the claim seems bleak.

Biotechnology

Five minutes with… Eva Kabir

2 March 2021 Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.

Biotechnology

Five minutes with… Irena Royzman

25 February 2021 Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.